Last Updated on August 10, 2022 by Neelam Singh
The climate provisions in the bill that the Senate passed this weekend are likely to be more consequential than anything else in the bill. They will lead to a sharp reduction in US greenhouse gas emissions, experts say, and help address arguably the world’s most pressing crisis.
But the other main spending portion of the bill – dealing with health care – is significant in its own right, and it has received much less attention, says David Leonhardt, a columnist, in the New York Times in analysis of the historic legislation.
On both the substance of the health care provisions and the politics of them, he said: “The provisions of the bill appear to be the most substantial changes to health policy since the passage of Obamacare in 2010.”
They are all but certain to become law, too. In the coming days, the House of Democrats are expected to pass the same bill that the Senate did, and President Biden has made clear he will quickly sign it, says the NYT.
The bill sets out to reduce Americans’ medical costs in two main ways. First, it uses federal subsidies to reduce the cost of both health insurance and prescription drugs. Second, the bill gives Medicare officials the power to negotiate with pharmaceutical companies, which will likely reduce the price that the companies charge for those drugs. Insulin dosage per unit is capped at $35.
For these reasons, the bill is effectively an effort to use the health care system to reduce economic inequality, much as Obamacare was. The bill’s benefits will flow overwhelmingly to poor, working-class and middle-class families. Its costs will be borne by increases in corporate taxes (which ultimately fall on shareholders, who skew wealthy) and reductions in the profits of pharmaceutical companies.
Some critics of the bill have argued that these profit reductions will lead pharmaceutical companies to spend less money developing future drugs and, in turn, to fewer promising treatments. And that’s a plausible concern, as per NYT as economic incentives matter.
But most experts believe that the pharmaceutical industry will remain plenty profitable even after the changes. The Congressional Budget Office – a nonpartisan body – estimates that the law will reduce the number of new drugs introduced over the next 30 years by about 1 per cent.
As per the bill’s main provisions and its benefits: With Medicare officials allowed to negotiate drug costs, it will mostly reduce Medicare’s spending, and thus, reduce the federal budget deficit. But there will probably be spillover into out-of-pocket costs, especially for people in Medicare.
The bill sets a $2,000 annual cap on the amount of money that any senior citizen pays for drugs. After the cap is hit, the federal government, private insurers and drug companies combined will pay the remaining bills. Today, drugs for cancer, multiple sclerosis, rheumatoid arthritis and some other diseases can cost people much more than $2,000 a year. The new provision will take effect in 2025 and will save a small percentage of older Americans thousands of dollars a year.
The bill caps out-of-pocket insulin expenses at $35 a month for people in Medicare; many now pay more than $50 a month. The bill also makes adult vaccines free for both seniors and people in Medicaid, starting next year.
For middle- and lower-income people, who buy private health-insurance plans through the Obamacare exchanges, federal subsidies will increase for three years. This change will help about 13 million people.
The political effects of the bill seem however seem less clear, the NYT says, citing political scientist Suzanne Mettler who contends that many forms of modern government remain “submerged” as Americans often do not realize when a federal policy is helping them, because the benefits come through tax credits or other shrouded forms.
Some of the benefits will flow through private insurance plans that people may not associate with a government programme, Cuban ski notes. Other provisions won’t take effect for a few years. Still others will spare people from facing a large medical bill, but they may not be aware that they wouldn’t have faced such a bill if Congress had not passed a new law.
All of which suggests that the law’s proponents will still have work to do after the House passes it and Biden signs it.
–IANS<br>ashe/vd
Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.
